- Home
- BIRD vs SAVA Comparison
BIRD vs SAVA Comparison
Compare BIRD & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- SAVA
- Stock Information
- Founded
- BIRD 2015
- SAVA 1998
- Country
- BIRD United States
- SAVA United States
- Employees
- BIRD N/A
- SAVA N/A
- Industry
- BIRD Apparel
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- SAVA Health Care
- Exchange
- BIRD Nasdaq
- SAVA Nasdaq
- Market Cap
- BIRD 89.7M
- SAVA 102.4M
- IPO Year
- BIRD 2021
- SAVA N/A
- Fundamental
- Price
- BIRD $6.36
- SAVA $2.15
- Analyst Decision
- BIRD Buy
- SAVA Hold
- Analyst Count
- BIRD 2
- SAVA 1
- Target Price
- BIRD $11.00
- SAVA $2.00
- AVG Volume (30 Days)
- BIRD 76.8K
- SAVA 607.2K
- Earning Date
- BIRD 11-05-2025
- SAVA 11-06-2025
- Dividend Yield
- BIRD N/A
- SAVA N/A
- EPS Growth
- BIRD N/A
- SAVA N/A
- EPS
- BIRD N/A
- SAVA N/A
- Revenue
- BIRD $170,646,000.00
- SAVA N/A
- Revenue This Year
- BIRD N/A
- SAVA N/A
- Revenue Next Year
- BIRD $4.20
- SAVA N/A
- P/E Ratio
- BIRD N/A
- SAVA N/A
- Revenue Growth
- BIRD N/A
- SAVA N/A
- 52 Week Low
- BIRD $3.93
- SAVA $1.15
- 52 Week High
- BIRD $14.56
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- BIRD 37.74
- SAVA 45.22
- Support Level
- BIRD $6.28
- SAVA $2.12
- Resistance Level
- BIRD $6.81
- SAVA $2.40
- Average True Range (ATR)
- BIRD 0.41
- SAVA 0.10
- MACD
- BIRD 0.09
- SAVA -0.02
- Stochastic Oscillator
- BIRD 20.56
- SAVA 13.79
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.